natgillin/translations-raw huggingface dataset:
Statistisk set havde færre eltrombopagpatienter behov for redningsmedicin under den randomiserede periode sammenlignet med placbopatienterne (19 % [12/63] vs.
Statistically fewer eltrombopag subjects required rescue treatment during the randomised period compared to placebo subjects (19% [12/63] vs.
Statistisk signifikant overlegent sammenlignet med placebo ved 0,05-niveauet uden multiplicitetsjustering.
Statistically significantly superior compared to placebo at the 0.05 level without multiplicity adjustment.
Statistisk signifikant overlegent sammenlignet med placebo ved 0,05-niveauet uden multiplicitetsjustering.
Statistically significantly superior compared with placebo at the 0.05 level without multiplicity adjustment.
Statistisk signifikante forskelle i ACR20 versus placebo var opnået ved uge 3.
Statistically significant difference in ACR 20 versus placebo was reached at Week 3.
Statistisk signifikante forskelle i virkning observeredes i hver af de to individuelle undersøgelser.
Statistically significant differences in efficacy were also observed in each of the 2 individual studies.
Statistisk signifikante forskelle i virkning sås i hvert af de to individuelle studier.
Statistically significant differences in efficacy were also observed in each of the 2 individual studies.
Statistisk superioritet blev også analyseret.
Statistical superiority was also analyzed.
Statistisk superioritet blev opnået efter 3 uger og opretholdt til og med uge 26 (p ≤ 0,001) som vist i tabel 6.
Sham (6.6%), p < 0.001. Statistical superiority was achieved at week 3 and maintained up to and including week 26 (p < 0.001) as shown in Table 6.
Status epilepticus
Pancreatitis
Status epilepticus* Krampe Koordinationsanomali* Nystagmus
Status epilepticus* Convulsion Coordination Abnormal* Nystagmus
Status epilepticus* Krampe Koordinationsanomali* Nystagmus Psykomotorisk hyperaktivitet
Status epilepticus* Convulsion Coordination Abnormal* Nystagmus
Status epilepticus* Kramper Koordinationsforstyrrelse* Nystagmus
Status epilepticus* Convulsion Coordination Abnormal* Nystagmus
Status epilepticus, ekstrapyramidal lidelse, hemiparese, ataksi, nedsat cognition, dysfasi, unormal gang, hyperestesi, hypoestesi, neurologisk
Status epilepticus, extrapyramidal disorder, hemiparesis, ataxia, cognition impaired, dysphasia, gait abnormal, hyperesthesia, hypoesthesia, neurological disorder (NOS), peripheral neuropathy
Status epilepticus, ekstrapyramidal lidelse, hemiparese, ataksi, nedsat cognition, dysfasi, unormal gang, hyperestesi, hypoestesi, neurologisk lidelse (NOS), perifer neuropati
Abdominal distension, fecal incontinence, gastrointestinal disorder (NOS), gastroenteritis, haemorrhoids
Status epilepticus, ekstrapyramidal lidelse, hemiparese, ataksi, nedsat cognition, dysfasi, unormal gang, hyperesthesia, hypoesthesia, neurologisk lidelse (NOS), perifer neuropati
hemiparesis, ataxia, cognition impaired, dysphasia, gait abnormal, hyperesthesia, hypoesthesia, neurological disorder (NOS), peripheral neuropathy
Status epilepticus, ekstrapyramidal lidelse, hemiparese, ataksi, nedsat kognition, dysfasi, unormal gang, hyperesthesia, hypoesthesia, neurologisk lidelse (NOS), perifer neuropati
Status epilepticus, extrapyramidal disorder, hemiparesis, ataxia, cognition impaired, dysphasia, gait abnormal, hyperesthesia, hypoesthesia, neurological disorder (NOS), peripheral neuropathy
Status epilepticus, extrapyramidale symptomer, hemiparese, ataksi, kognitive forstyrrelser, dysfasi, unormal gang, hyperæstesi, hypoæstesi,
Status epilepticus, extrapyramidal disorder, hemiparesis, ataxia, cognition impaired, dysphasia, gait abnormal, hyperesthesia, hypoesthesia, neurological disorder (NOS), peripheral neuropathy
Status for EGFR-mutation og kliniske karakteristika
EGFR mutation status and clinical characteristics
Status for RET-mutation
RET mutation status
Status for RET-mutation skal bestemmes i henhold til en prædefineret mutations- analyse, hvor testtypen og de exoner, der skal analyseres, fastsættes på forhånd i protokollen.
RET mutation status should be assessed according to pre-defined mutational analysis, where type of test and exons to be analyzed are protocol pre-specified.
Status for RET-mutation:
RET mutation status:
Status for YMDD-mutation- HBV
YMDD mutant HBV status
Status skal rapporteres årligt i hver årlig genvurderingsansøgning
Status to be reported annually within each annual re-assessment application
Status som ’CYP2C19 poor metaboliser’ er forbundet med nedsat respons på clopidogrel.
CYP2C19 poor metaboliser status is associated with diminished response to clopidogrel.
Statuslyset vil blive ved med at blinke grønt, indtil batteriet løber tør eller er fjernet.
The status light will remain green and will continue to flash until the battery runs out or is removed.
Statuslyset vil skifte fra grønt til langsomt blinkende orange for at vise, at injektionen er begyndt.
The light will turn from green to flashing orange slowly indicating that injection has begun.
Statusopdate- ring skal indsendes hver
Recruitment status update to be submitted every
Stavelo anvendes til behandling af Parkinsons sygdom.
Stalevo is used to treat adults with Parkinson’s disease.
Stavudin (40 mg én gang dagligt)
Stavudine (40 mg once daily)
stavudin forventes ikke at påvirke
stavudine is not expected to
Stavudin hæmmer ikke de væsentligste CYP-isoformer CYP1A2, CYP2C9, CYP2C19, CYP2D6 og CYP3A4; det er derfor ikke sandsynligt, at klinisk signifikante lægemiddelinteraktioner vil optræde med lægemidler, der metaboliseres via disse metaboliseringsveje.
Stavudine does not inhibit the major cytochrome P450 isoforms CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4; therefore, it is unlikely that clinically significant drug interactions will occur with medicines metabolised through these pathways.
Stavudin og Viramune kan co- administreres uden dosisjustering.
Stavudine and Viramune can be co- administered without dose adjustments.
stavudin-eksponeringen signifikant.
ignificantly alter the exposure of
stavudin-koncentrationerne.
concentrations was observed.
Stavudinbehandling er forbundet med adskillige, alvorlige bivirkninger, som for eksempel laktatacidose, lipoatrofi og polyneuropati, hvor en potentiel underliggende mekanisme er mitokondriel toksicitet.
Stavudine therapy is associated with several severe adverse reactions, such as lactic acidosis, lipoatrophy and polyneuropathy, for which a potential underlying mechanism is mitochondrial toxicity.
Stavudinbehandling kan udvælge og/eller opretholde thymidinanaloge mutationer (TAM’er) forbundet med zidovudinresistens.
Stavudine treatment can select for and/or maintain thymidine analogue mutations (TAMs) associated with zidovudine resistance.
Stavudins CSF/plasma ratio lå mellem 16%-125% (middel på 59%±35%) 2-3 timer efter administration.
Two to three hours post-dose, CSF/plasma ratios of stavudine ranged from 16% to 125% (mean of 59%±35%).
Stavudins påvirkning af nukleosidanalogers fosforyleringskinetik, bortset fra zidovudin, er ikke undersøgt.
Stavudine’s influence on the phosphorylation kinetics of nucleoside analogues other than zidovudine has not been investigated.
Stayveer
Strength
STAYVEER 125 mg filmovertrukne tabletter
STAYVEER 125 mg film-coated tablets
STAYVEER 125 mg filmovertrukne tabletter: Aktivt stof: bosentan som monohydrat.
STAYVEER 125 mg film-coated tablets: The active substance is bosentan as monohydrate.
STAYVEER 62, 5 mg filmovertrukne tabletter: Aktivt stof: bosentan som monohydrat.
STAYVEER 62.5 mg film-coated tablets: The active substance is bosentan as monohydrate.
STAYVEER 62,5 mg filmovertrukne tabletter
STAYVEER 62.5 mg film-coated tablets
STAYVEER anbefales ikke til pædiatriske patienter med systemisk sklerose og aktiv finger/tå- sårssygdom.
STAYVEER is not recommended in paediatric patients with systemic sclerosis and ongoing digital ulcer disease.
STAYVEER behandling må ikke påbegyndes hos kvinder i den fertile alder, medmindre de bruger pålidelig prævention, og en graviditetsprøve inden behandlingens start er negativ
STAYVEER treatment must not be initiated in women of childbearing potential unless they practise reliable contraception and the result of the pre-treatment pregnancy test is negative
Stayveer er blevet anvendt i fire hovedundersøgelser ved PAH: to undersøgelser hos i alt 245 voksne med sygdom, der var af klasse III eller IV og enten var primær eller skyldtes sklerodermi, én undersø- gelse med 54 voksne med PAH af klasse III ved medfødte hjertefejl, og én undersøgelse med 185 pa- tienter med sygdom af klasse II.
In PAH, Stayveer has been studied in four main studies: two in a total of 245 adults with class III or IV disease that was either primary or caused by scleroderma, one in 54 adults with class III PAH that was associated with congenital heart defects, and one in 185 patients with class II disease.
Stayveer er et lægemiddel, der indeholder det aktive stof bosentan.
Stayveer is a medicine that contains the active substance bosentan.
STAYVEER er kontraindiceret til patienter med moderat til svært nedsat leverfunktion (se pkt.
STAYVEER is contraindicated in patients with moderate to severe liver dysfunction (see sections 4.3,
Stayveer fås kun på recept, og behandlingen bør kun iværksættes og overvåges af en læge med erfa- ring i behandling af PAH eller systemisk sklerose.
Stayveer can only be obtained with a prescription and treatment should only be started and monitored by a doctor who has experience in the treatment of PAH or systemic sclerosis.
Stayveer kan desuden anvendes til voksne med systemisk sklerose, hos hvem sygdommen har med- ført sår på fingre og tæer som følge af nedsat blodcirkulation Stayveer vil blive anvendt til at nedsætte antallet af nye sår på fingre og tæer.
Stayveer can also be used in adults with systemic sclerosis in whom poor blood circulation caused by the disease has led to the development of ‘digital ulcers’ (sores on the fingers and toes).
Stayveer må ikke anvendes hos patienter med visse leverproblemer, patienter, der er gravide eller kan blive gravide, fordi de ikke bruger pålidelig svangerskabsforebyggelse, eller hos patienter, der får ci- closporin A (et lægemiddel, der virker på immunsystemet).
Stayveer must not be used in patients who have certain liver problems, who are pregnant or could become pregnant because they are not using reliable contraceptive methods or who are taking ciclosporin A (a medicine that acts on the immune system).
STAYVEER må ikke anvendes ved Child Pugh Klasse B eller C, dvs. moderat til svært nedsat leverfunktion
STAYVEER should not be used in Child Pugh Class B or C, i.e. moderate to severe hepatic impairment.
Stayveer udvider derfor blodkarrene.
Stayveer therefore causes blood vessels to expand.
Stayveer var mere effektivt end placebo til at nedsætte dannelsen af nye sår på finger og tæer.
Stayveer was more effective at reducing the development of new digital ulcers than placebo.
STAYVEERs virkning er ikke undersøgt hos patienter med svær pulmonal arteriel hypertension.
The efficacy of STAYVEER has not been established in patients with severe pulmonary arterial hypertension.
Steady state AUC, Cmaks. og Cmin steg mindre end dosis-proportionelt og de enkelte eksponeringer overlappede i betydelig grad hinanden ved 800 mg og 1.200 mg, hvilket tyder på reduceret absorption ved højere doser.
Steady state AUC, Cmax and Cmin increased in a less-than dose-proportional manner and individual exposures overlapped substantially at 800 mg and 1,200 mg, suggesting diminished absorption at higher doses.
Steady state AUC0-12 t var 2349850 ngt/ml.
The steady-state AUC0-12h was 2349±850 ng•h/ml.
Steady state blev nået efter 4 dage til 5 dage med en daglig administration af canagliflozin 100 mg til 300 mg.
Steady-state was reached after 4 days to 5 days of once-daily dosing with canagliflozin 100 mg to 300 mg.
Steady state blev opnået inden for to uger.
Steady-state was achieved within two weeks.
Steady state blev opnået på dag 15.
Steady-state was achieved by Day 15.
Steady state data fra et begrænset antal patienter i mindre fase II-studier indikerede dog at:
However, steady-state data from a limited number of patients in smaller phase II studies indicated that:
Steady state farmakokinetik af tenofovir blev evalueret hos 8 hiv 1-inficerede unge patienter (i alderen 12 til < 18 år) med kropsvægt ≥ 35 kg og hos 23 hiv 1-inficerede børn i alderen 2 til < 12 år.
Steady-state pharmacokinetics of tenofovir were evaluated in 8 HIV-1 infected adolescent patients (aged 12 to < 18 years) with body weight ≥ 35 kg and in 23 HIV- 1 infected children aged 2 to < 12 years.
Steady state farmakokinetiske parametre for lopinavir hos hiv-inficerede patienter med mild til moderet svækket leverfunktion blev sammelignet med de hiv-inficerede patienter med normal leverfunktion i et multidosis studie med lopinavir/ritonavir 400/100 mg to gange daglig.
The steady state pharmacokinetic parameters of lopinavir in HIV-infected patients with mild to moderate hepatic impairment were compared with those of HIV-infected patients with normal hepatic function in a multiple dose study with lopinavir/ritonavir 400/100 mg twice daily.
Steady state forekommer efter 2-3 dages dosering.
Steady state will occur after 2–3 days of dose administration.
Steady state indtræffer efter 2 ugers behandling.
Steady state is reached after 2 weeks of treatment.
Steady state opnås på behandlingens 2. dag.
Steady state is achieved on the second day of treatment.
Steady state peak plasmakoncentration opnået efter tørpulver-inhalation af 400 µg aclidiniumbromid af patienter med KOL var cirka 224 pg/ml.
Steady state peak plasma concentrations achieved after dry powder inhalation by COPD patients of 400 µg aclidinium bromide were approximately 224 pg/mL.
Steady state plasmakoncentrationerne af drotrecogin alfa (aktiveret) er proportionale med infusionshastigheden i intervallet 12 g/kg/time til 48 g/kg/time.
Plasma drotrecogin alfa (activated) steady-state concentrations are proportional to the infusion rate over a range of infusion rates from 12 g/kg/hr to 48 g/kg/hr.
Steady state- fordelingsrummet er 10 liter.
The steady state volume of distribution is 10 l.
Steady state- fordelingsrummet og den totale clearance er henholdsvis 10 liter og 0,6 liter/time.
The steady state volume of distribution and total clearance are 10 l and 0.6 l/h, respectively.
Steady state- koncentration af ustekinumab blev nået lige inden den anden vedligeholdelsesdosis.
Steady state ustekinumab concentration was achieved by the start of the second maintenance dose.
Steady state- koncentrationer opnås inden for 7 dage med dosering af mirabegron én gang dagligt.
Steady state concentrations are achieved within 7 days of once daily dosing with mirabegron.
Steady state-AUC steg 2,5–3 gange, da dosis blev øget fra 500 mg til 1.000 mg to gange dagligt.
There was a 2.5- to 3-fold increase in steady-state AUC as the dose was increased from 500 mg to 1000 mg twice daily.
Steady state-digoxinkoncentrationer er blevet øget (1,3 gange øgning i maksimal observeret plasmakoncentration [Cmax] og 1,2 gange øgning af arealet under tidskurven for plasmakoncentration over doseringsintervallet [AUC) ved samtidig administration af flere doser tolvaptan på 60 mg én gang dagligt.
Steady state digoxin concentrations have been increased (1.3-fold increase in maximum observed plasma concentration [Cmax] and 1.2-fold increase in area under the plasma concentration-time curve over the dosing interval [AUC) when co administered with multiple once daily 60 mg doses of tolvaptan.
Steady state-digoxinkoncentrationer er set øget (1,3 gange øgning i maksimal observeret plasmakoncentration [Cmax] og 1,2 gange øgning af arealet under tidskurven for plasmakoncentration over doseringsintervallet [AUCτ]) ved samtidig administration af flere doser tolvaptan på 60 mg én gang dagligt.
Steady state digoxin concentrations were increased (1.3-fold in maximum observed plasma concentration [Cmax] and 1.2-fold in area under the plasma concentration-time curve over the dosing interval [AUCτ]) when co administered with multiple once daily 60 mg doses of tolvaptan.
Steady state-distributionsvolumen for ticagrelor er 87,5 l.
The steady state volume of distribution of ticagrelor is 87.5 l.
Steady state-koncentrationer af lurasidon nås inden for 7 dages behandling.
Steady-state concentrations of lurasidone are reached within 7 days of starting lurasidone.
Steady state-niveauer nås i løbet af 7 dage med minimal akkumulation.
Steady state levels of cinacalcet are achieved within 7 days with minimal accumulation.
Steady state-serumkoncentration af basalkomponenten (insulin degludec) nås efter 2- 3 dages daglig administration af Ryzodeg.
Steady state serum concentration of the basal component (insulin degludec) is reached after 2–3 days of daily Ryzodeg administration.
Steady state-serumkoncentration nås efter 2-3 dages daglig administration af Tresiba.
Steady state serum concentration is reached after 2–3 days of daily Tresiba administration.
Steady- state gennemsnitlige værdier for Cmax, AUCtau og Ctrough (gennemsnit ± SD) efter flere doser af elvitegravir plus en ritonavir-boosted proteasehæmmer (150 mg elvitegravir med darunavir eller fosamprenavir, 85 mg elvitegravir med atazanavir eller lopinavir) hos hiv-1-inficerede personer var hhv.
The steady-state mean Cmax, AUCtau, and Ctrough (mean ± SD) following multiple doses of elvitegravir plus a ritonavir-boosted protease inhibitor (150 mg elvitegravir with darunavir or fosamprenavir; 85 mg elvitegravir with atazanavir or lopinavir) in HIV-1 infected subjects were 1.4 ± 0.39 μg/mL, 18 ± 6.8 μg•h/mL, and
Steady- state-plasmaniveauerne opnås efter vedvarende administration i 7-8 dage.
Steady-state plasma levels are reached after continuous administration for 7-8 days.
Steady-state AUC, Cmax og Cmin for den aktive carbamazepinepoxid- metabolit forblev uændret.
The steady-state AUC, Cmax and Cmin of the active carbamazepine epoxide metabolite remained unchanged.
Steady-state blev opnået inden for to uger.
Steady-state was achieved within two weeks.
Steady-state farmakokinetikken hos patienter på 65 år og derover ligner den der ses hos unge personer.
Steady state pharmacokinetics are similar in patients age 65 and over and young subjects.
Steady-state for AUC og Cmin blev nået efter 12 uger og efter 10 uger for Cmax.
Steady state was reached after 12 weeks for AUC and Cmin, and after 10 weeks for Cmax.
Steady-state fordelingsvolumen (Vss) bestemt efter intravenøs administration af 1–2 mg/kg lå fra omkring 4,4 til 7,0 l/kg.
The volume of distribution at steady-state (Vss) determined after intravenous administration at 1–2 mg/kg ranged from approximately 4.4 to 7.0 l/kg.
Steady-state koncentration nås efter 7-8 dage.
Steady-state plasma levels are reached after continuous administration for 7–8 days.
Steady-state niveauer blev opnået på 2 uger, og tiden til maksimal koncentration (Tmax) varierede mellem 6 og 9 timer efter sidste påføring.
Steady-state levels were achieved in 2 weeks and time to maximal concentrations (Tmax) ranged between 6 and 9 hours after last application.
Steady-state opnås 6 - 10 dage efter én gang daglig dosering med  2 gange akkumulering.
Steady-state is achieved between 6-10 days after once daily dosing with  2 times accumulation.
Steady-state opnås efter 4 - 7 dages dosering.
Steady state is achieved after 4-7 days of dosing.
Steady-state opnås efter 4-7 dages administration.
Steady-state is achieved after 4-7 days of dosing.
Steady-state opnås efter 4-7 dages dosering.
Steady state is achieved after 4-7 days of dosing.
Steady-state opnås efter 4-7 dages dosering.
Steady state is achieved after 4–7 days of dosing.
Steady-state plasma- koncentrationen nås i løbet af 3 dage efter påbegyndelse af behandling 1 gang dagligt.
Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily dosing regimen.
Steady-state plasma- koncentrationer opnås indenfor 5 dage med dosering en gang dagligt.
Steady-state plasma concentrations are attained within 5 days of once-daily dosing.
Steady-state plasmakoncentrationen nås i løbet af 3 dage efter påbegyndelse af behandling 1 gang dagligt.
Steady- state plasma concentrations are attained within 3 days after initiation of a once-daily dosing regimen.
Steady-state serumkoncentrationer af ustekinumab hos patienter med psoriasis blev opnået i uge 28 efter initiale subkutane doser i uge 0 og 4 efterfulgt af doser hver 12. uge.
In patients with psoriasis, steady-state serum concentrations of ustekinumab were achieved by week 28 after initial subcutaneous doses at Weeks 0 and 4 followed by doses every 12 weeks.
Steady-state tilstande opnås inden for 3–5 dage.
Steady-state conditions are reached within 3–5 days.
Steady-state tipranavir/r:
Steady-state tipranavir/r
Steady-state-eksponering øges ikke dosis-proportionelt.
Steady-state exposure does not increase in a dose-proportional manner.
Steady-state-koncentrationerne
Steady-state concentrations was
Steady-state-plasmaniveauerne opnås efter vedvarende administration i 7-8 dage.
Steady-state plasma levels are reached after continuous administration for 7–8 days.
Steady-statetipranavir/r:
pantoprazole plasma concentrations
Steady-statetipranavir/r:
Rabeprazole
Steady–state for ipilimumab blev nået ved den tredje dosis.
Ipilimumab steady-state was reached by the third dose.
Stearinsyre Butylhydroxytoluen (E321)
Butyl hydroxytoluene (E321)
Stearylalkohol 31,0 mg/g creme
Stearyl alcohol 31.0 mg/g cream
Stearylalkohol;
Stearyl alcohol;
Steatose var signifikant forbedret hos de patienter, der var inficeret med hcv Genotype 3.
Steatosis was significantly improved in patients infected with HCV Genotype 3.
Steatose var signifikant forbedret hos de patienter, der var inficeret med hcv- genotype 3.
Steatosis was significantly improved in patients infected with HCV Genotype 3.
sted, hvis de potentielle
be initiated if the potential
stedet
Amnesia
stedet
site conditions
Stedet på sclera skal roteres ved efterfølgende injektioner.
A different scleral site should be used for subsequent injections.
Stedet på sklera skal roteres ved efterfølgende injektioner.
0.05 ml is then delivered; a different scleral site should be used for subsequent injections.
Stelara 130 mg koncentrat til infusionsvæske gives på et hospital eller en klinik, og patienterne skal ikke opbevare eller håndtere det.
Stelara 130 mg concentrate for solution for infusion is given in a hospital or clinic and patients should not need to store or handle it.
STELARA 130 mg koncentrat til infusionsvæske, opløsning Ustekinumab
STELARA 130 mg concentrate for solution for infusion Ustekinumab
STELARA 45 mg injektionsvæske, opløsning
STELARA 45 mg solution for injection
STELARA 45 mg injektionsvæske, opløsning i fyldt injektionssprøjte
STELARA 45 mg solution for injection in pre-filled syringe
STELARA 45 mg injektionsvæske, opløsning i fyldt injektionssprøjte ustekinumab
STELARA 45 mg solution for injection in pre-filled syringe ustekinumab
STELARA 45 mg injektionsvæske, opløsning Injektionsvæske, opløsning.
STELARA 45 mg solution for injection Solution for injection.
STELARA 45 mg injektionsvæske, opløsning STELARA 90 mg injektionsvæske, opløsning
STELARA 45 mg solution for injection STELARA 90 mg solution for injection
STELARA 45 mg injektionsvæske, opløsning ustekinumab
STELARA 45 mg solution for injection ustekinumab
STELARA 90 mg injektionsvæske, opløsning
STELARA 90 mg solution for injection
STELARA 90 mg injektionsvæske, opløsning i fyldt injektionssprøjte
STELARA 90 mg solution for injection in pre-filled syringe
STELARA 90 mg injektionsvæske, opløsning i fyldt injektionssprøjte Injektionsvæske, opløsning.
STELARA 90 mg solution for injection in pre-filled syringe Solution for injection.
STELARA 90 mg injektionsvæske, opløsning i fyldt injektionssprøjte ustekinumab
STELARA 90 mg solution for injection in pre-filled syringe ustekinumab
STELARA 90 mg injektionsvæske, opløsning Injektionsvæske, opløsning.
STELARA 90 mg solution for injection Solution for injection.
STELARA 90 mg injektionsvæske, opløsning ustekinumab
STELARA 90 mg solution for injection ustekinumab